Darbepoetin Alfa: A Viewpoint by Allen R. Nissenson

Nissenson, A.R.
November 2001
Drugs;Nov2001, Vol. 61 Issue 14, p2105
Academic Journal
Comments on darbepoetin alfa, a haematopoietic stimulating protein with applications to a wide variety of types of anemia. Background on the development of the chemical; Tolerability profile; Benefits of a longer-acting haematopoietic stimulator according to the types of patients likely to receive the substance.


Related Articles

  • Anemia in patients with cancer: Incidence, causes, impact, management, and use of treatment guidelines and protocols. Schwartz, Rowena N. // American Journal of Health-System Pharmacy;2/1/2007 Supplement, Vol. 64, pS5 

    Purpose. The incidence, etiology, impact, and considerations in developing guidelines for treating anemia in patients with cancer are described. Summary. Anemia is common in patients with cancer. The incidence and severity of anemia depend on the type and extent of the malignancy; the type,...

  • Erythropoietic Growth Factors in Oncology-Associated Anemia Part 2: Contrasting Perspectives on Guidelines.  // Formulary;May2004 Supp, Vol. 39, p1 

    Part II. Focuses on the development and implementation of formulary decisions in oncology-associated anemia and the strategies for maintaining high guideline compliance, including therapeutic interchange and pharmacist-managed therapy. Etiology, treatment and outcomes of oncology-associated...

  • Management of Anaemia: A Critical and Systematic Review of the Cost Effectiveness of Erythropoiesis-Stimulating Agents. Mei Sheng Duh; Weiner, Jennifer R.; White, Leigh Ann; Lefebvre, Patrick; Greenberg, Paul E. // PharmacoEconomics;2008, Vol. 26 Issue 2, p99 

    Erythropoiesis-stimulating agents (ESAs) are genetically engineered forms of erythropoietin that are used in the treatment of anaemia. Their successful use in the treatment of anaemia associated with renal disease, cancer and other diseases, as well as the development of multiple agents, has...

  • Health Economic Evaluation of Treating Anemia in Cancer Patients Receiving Chemotherapy: A Study in Belgian Hospitals. Spaepen, Erik; Demarteau, Nadia; Van Belle, Simon; Annemans, Lieven // Oncologist;May2008, Vol. 13 Issue 5, p596 

    Background. Erythropoiesis-stimulating agents (ESAs) are used in chemotherapy-induced anemia (CIA) with the goal of improving quality of life and preventing RBC transfusions. This retrospective database study compared the three currently available ESAs, epoetin alfa (EPO-A), epoetin beta...

  • The new FDA label for erythropoietin treatment: How does it affect hemoglobin target? Fishbane, S.; Nissenson, A. R. // Kidney International;Oct2007, Vol. 72 Issue 7, p806 

    The erythropoietin analogs have been an important advance for the treatment of the anemia of kidney disease, resulting in reduced need for blood transfusion and improved quality of life. Recent studies, however, have indicated risks associated with targeting higher levels of hemoglobin (Hb). As...

  • The anemia epidemic. Friedland, Ilene // Working Mother;Jul93, p18 

    Discusses iron-deficiency anemia. Symptoms; Misguided eating habits; Higher risk for women; Recommended dietary allowance; Prevention; Two types of iron; Iron-rich foods; Tips for higher iron absorption; Advice on iron supplements.

  • When thinking becomes a little `rusty,' consider iron supplements. Dolby, Victoria // Better Nutrition;Sep97, Vol. 59 Issue 9, p20 

    Presents information on anemia, while focusing on the benefit of using iron as a treatment for the disorder. Views of Doctor Anne B. Bruner and colleagues from Johns Hopkins University School of Medicine on the issue; Reason for the occurrence of anemia; Reference to a study of 716 teens;...

  • More anemic patients can now be treated with epoetin alfa. Hurley, Mary Lou // RN;Aug93, Vol. 56 Issue 8, p78 

    Reports on the Food and Drug Administration's approval of epoetin alfa (Procrit) for the treatment of anemia related to chemotherapy in patients with non-myeloid malignancies. Greater hematocrit response for patients receiving epoetin alfa than patients receiving a placebo; Adverse reactions;...

  • Resource Utilisation and Time Commitment Associated with Correction of Anaemia in Cancer Patients Using Epoetin Alfa. Lynch, Donna-Marie; Slaven, Tracey // Clinical Drug Investigation;2007, Vol. 27 Issue 9, p661 

    A correction to the article "Resource Utilisation and Time Commitment Associated With Correction of Anaemia in Cancer Patients Using Epoetin Alfa," by K. R. Meehan, is presented.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics